BMRN vs. VTRS: BioMarin Pharmaceutical vs. Viatris Stock Comparison
How do BioMarin Pharmaceutical (BMRN) and Viatris (VTRS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
BioMarin Pharmaceutical (BMRN) and Viatris (VTRS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BMRN is classified in Biotechnology while VTRS is classified in Pharmaceuticals.
| Profile Item | BMRN | VTRS |
|---|---|---|
| Name | BioMarin Pharmaceutical Inc. | Viatris Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Pharmaceuticals |
| GICS Sub-Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 10.85 billion USD | 22.83 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | July 26, 1999 | March 17, 1980 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BMRN | VTRS |
|---|---|---|
| Total Return (1Y) | 8.82% | 108.98% |
| Total Return (3Y, Annualized) | -12.54% | 36.75% |
| Total Return (5Y, Annualized) | -7.51% | 11.59% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | BMRN | VTRS |
|---|---|---|
| Volatility (1Y, Annualized) | 35.50% | 32.53% |
| Beta (5Y) | 0.24 | 0.86 |
| Max Drawdown (5Y) | -57.64% | -45.69% |
| Avg. Volume (3M) | 2.28M | 8.87M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BMRN | VTRS |
|---|---|---|
| Sharpe Ratio (1Y) | 0.13 | 3.22 |
| Sortino Ratio (1Y) | 0.23 | 5.63 |
Profitability
ROE (TTM)
Both BioMarin Pharmaceutical (BMRN) at -0.31% and Viatris (VTRS) at -4.21% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.31%
- Max
- 109.18%
- Q3
- 6.23%
- BMRN
- -0.31%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
-4.21%
- Max
- 109.18%
- Q3
- 6.23%
- VTRS
- -4.21%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both BioMarin Pharmaceutical (BMRN) at -0.52% and Viatris (VTRS) at -4.13% report negative net margin values, usually indicating net losses over the period.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.52%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- BMRN
- -0.52%
- Q1
- -4.14%
- Min
- -17.05%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
-4.13%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- VTRS
- -4.13%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
BioMarin Pharmaceutical (BMRN) at 26.58% operates in the top operating margin quartile, ahead of Viatris (VTRS) at 13.85%, which runs around its industry’s norm.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.58%
- Max
- 83.12%
- BMRN
- 26.58%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.85%
- Max
- 83.12%
- Q3
- 14.77%
- VTRS
- 13.85%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | BMRN | VTRS |
|---|---|---|
| ROE (TTM) | -0.31% | -4.21% |
| ROA (TTM) | 3.89% | 2.91% |
| Net Margin (TTM) | -0.52% | -4.13% |
| Operating Margin (TTM) | 26.58% | 13.85% |
| Gross Margin (TTM) | 53.21% | 41.13% |
Growth
Revenue Growth
BioMarin Pharmaceutical (BMRN) at 12.87% is around its peer norm for revenue growth, while Viatris (VTRS) at -2.98% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Only one side can be read here: BioMarin Pharmaceutical (BMRN) reports EPS growth of -18.55%, ranked against its industry; Viatris (VTRS) has no EPS growth figure this period.
Growth Metrics
| Metric | BMRN | VTRS |
|---|---|---|
| Revenue Growth (YoY) | 12.87% | -2.98% |
| Revenue Growth (3Y CAGR) | 15.40% | -4.20% |
| EPS Growth (YoY) | -18.55% | -- |
| EPS Growth (3Y CAGR) | 33.89% | -- |
Financial Strength
Current Ratio (MRQ)
Both BioMarin Pharmaceutical (BMRN) at 2.44 and Viatris (VTRS) at 1.55 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.44
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- BMRN
- 2.44
- Min
- 0.10
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.55
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- VTRS
- 1.55
- Min
- 0.10
Debt / Equity (MRQ)
Both BioMarin Pharmaceutical (BMRN) at 0.67 and Viatris (VTRS) at 0.99 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.67
- Max
- 1.42
- BMRN
- 0.67
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.99
- Max
- 1.42
- VTRS
- 0.99
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BMRN | VTRS |
|---|---|---|
| Current Ratio (MRQ) | 2.44 | 1.55 |
| Debt / Equity (MRQ) | 0.67 | 0.99 |
| Net Debt / EBITDA | 4.04 | 2.64 |
Dividends
Dividend Yield (TTM)
BioMarin Pharmaceutical (BMRN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Viatris (VTRS) reports a yield of 2.53%, ranking against industry peers normally.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.53%
- VTRS
- 2.53%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings; BioMarin Pharmaceutical (BMRN) pays no dividend (payout 0.00%).
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
960.00%
- VTRS
- 960.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BMRN | VTRS |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 2.53% |
| Dividend Payout Ratio (TTM) | 0.00% | 960.00% |
Valuation
P/E Ratio (TTM)
Neither BioMarin Pharmaceutical (BMRN) nor Viatris (VTRS) reports a P/E ratio value for this period, so a direct comparison isn’t possible.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- BMRN
- --
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- VTRS
- --
P/S Ratio (TTM)
Both BioMarin Pharmaceutical (BMRN) at 2.97 and Viatris (VTRS) at 1.55 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.97
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- BMRN
- 2.97
- Min
- 0.01
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.55
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- VTRS
- 1.55
- Min
- 0.01
P/B Ratio (MRQ)
Viatris (VTRS) at 1.67 sits in the lower P/B ratio quartile against book while BioMarin Pharmaceutical (BMRN) at 1.73 is valued near its industry’s middle — VTRS is cheaper on assets, though weigh it against ROE and asset quality.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.73
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- BMRN
- 1.73
- Q1
- 1.69
- Min
- -5.59
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.67
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- VTRS
- 1.67
- Min
- -5.59
Valuation Metrics
| Metric | BMRN | VTRS |
|---|---|---|
| P/E Ratio (TTM) | -- | -- |
| P/S Ratio (TTM) | 2.97 | 1.55 |
| P/B Ratio (MRQ) | 1.73 | 1.67 |
| Free Cash Flow Yield (TTM) | -0.15% | 13.84% |